Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

Rhea-AI Summary

Molecular Partners (NASDAQ:MOLN) will present trial-in-progress posters on its DLL3-targeting radio-DARPin MP0712 at ASCO 2026 in Chicago and SNMMI 2026 in Los Angeles.

The ongoing US Phase 1/2a trial is dosing the first cohort, with initial clinical data expected in 2026.

Market Context

This announcement highlights active Phase 1/2a development of MP0712, a DLL3‑targeting Radio‑DARPin ...

Analysis

This announcement highlights active Phase 1/2a development of MP0712, a DLL3‑targeting Radio‑DARPin using 212Pb, with first‑cohort dosing underway and ASCO/SNMMI trial‑in‑progress posters. Earlier 203Pb imaging showed specific tumor uptake, supporting continued clinical work. Investors may track upcoming 2026 data disclosures, safety findings, and signs of efficacy, while keeping in mind the company’s broader DARPin pipeline and the inherent uncertainty of early oncology trials.

Key Figures

DLL3 tumor expression: >85% of tumors Trial phase: Phase 1/2a Therapeutic isotope: 212Pb +4 more

7 metrics

DLL3 tumor expression >85% of tumors DLL3 expression in SCLC and other aggressive neuroendocrine tumors

Trial phase Phase 1/2a US multicenter study of MP0712 in DLL3-expressing cancers

Therapeutic isotope 212Pb Alpha-emitting isotope used in MP0712 Radio-DARPin therapy

Diagnostic isotope 203Pb Used for first patient imaging and dosimetry data in MP0712

ClinicalTrials.gov ID NCT07278479 Identifier for MP0712 Phase 1/2a trial

ASCO 2026 poster time 1:30–4:30 pm ASCO 2026 MP0712 poster session on May 30, 2026

SNMMI 2026 poster time 11:30am–12:15pm SNMMI 2026 MP0712 poster session on June 2, 2026

Previous Clinical trial Reports

5 past events · Latest: May 01 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 01	Phase 1 data MP0317	Positive	+0.2%	Published Phase 1 MP0317 data in Nature Cancer showing safety and biomarker activity.
Jan 11	JPM clinical update	Positive	+1.6%	Highlighted cleared IND, MP0712 trial start, and solid cash runway at JPM conference.
Dec 07	MP0533 AML update	Positive	-7.0%	Presented updated MP0533 Phase 1/2a AML data with responses in heavily pretreated patients.
Jun 22	MP0726 preclinical data	Positive	-8.0%	Reported preclinical MP0726 mesothelin-targeting Radio-DARPin biodistribution and tumor uptake data.
Jun 11	Positive MP0533 data	Positive	+8.0%	Announced positive Phase 1/2a MP0533 AML responses and acceptable safety at EHA 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial news has produced mixed reactions, with both strong gains and notable selloffs; average same-tag moves have been slightly negative despite generally positive clinical narratives.

Recent Company History

Over the last year, Molecular Partners has repeatedly highlighted progress across its DARPin pipeline, particularly Radio-DARPin candidates and early‑stage oncology trials. Clinical‑trial‑tagged updates, including MP0317 Phase 1 data on May 01, 2026 and MP0533 AML data in June–December 2025, often reported favorable safety and activity signals but generated uneven share reactions. Today’s MP0712 Phase 1/2a dosing and ASCO/SNMMI presentation update fits this pattern of incremental validation in early-stage programs rather than a single transformational milestone.

Key Terms

darprin therapeutics, radio-darpin therapy, delta-like ligand 3 (dll3), small cell lung cancer (sclc), +4 more

8 terms

darprin therapeutics medical

"a novel class of custom-built protein drugs known as DARPin therapeutics"

Darprin Therapeutics is a biopharmaceutical company that researches and develops medical treatments and technologies. For investors, the company’s value depends largely on the success of its drug development pipeline, regulatory approvals, clinical trial results, and commercial partnerships — similar to backing a product inventor where each milestone can significantly increase or decrease the company’s future revenue potential.

radio-darpin therapy medical

"MP0712 is a 212Pb-based Radio-DARPin Therapy (RDT) candidate targeting"

A radio‑DARPin therapy pairs a small, engineered binding protein (a DARPin) with a radioactive atom so the radiation is carried directly to diseased cells, most often tumors. For investors, this matters because it promises more precise treatment with potentially higher effectiveness and fewer side effects than traditional chemotherapy or external radiation, which affects clinical risk, regulatory hurdles, market potential and pricing—think a guided missile instead of carpet bombing.

delta-like ligand 3 (dll3) medical

"targeting the tumor-associated protein delta-like ligand 3 (DLL3) for the treatment"

Delta-like ligand 3 (DLL3) is a protein found on the surface of some cells that helps control cell growth and communication. Investors care because DLL3 can serve as a biomarker or drug target in certain cancers: its presence may identify patients who could benefit from targeted therapies or diagnostics, which affects the commercial potential of biotech drugs and diagnostic tests much like a lock that a specific key-shaped drug is designed to fit.

small cell lung cancer (sclc) medical

"for the treatment of patients with small cell lung cancer (SCLC) and other"

An aggressive type of lung cancer made of small, fast-dividing cells that typically grows and spreads quickly beyond the lungs. It matters to investors because its rapid course and limited treatment options make new drugs, diagnostic tests, or approvals potentially high-impact catalysts for healthcare companies — similar to how a breakthrough tool can change the outcome in a fast-moving crisis — affecting sales, regulatory risk, and market valuation.

dosimetry medical

"presented first patient imaging and dosimetry data on MP0712 at the 8th"

Dosimetry is the measurement and calculation of how much ionizing radiation is absorbed by people, tissues, or devices, similar to a thermostat tracking temperature in different rooms to know where and how much heat is present. Investors should care because accurate dosimetry underpins safety, treatment effectiveness, regulatory approval, and liability for products and services that use radiation—affecting market access, costs, and commercial risk.

named patient access program regulatory

"as part of a Named Patient Access Program under the legal framework"

A named patient access program lets a doctor request an unapproved or not-yet-marketed medicine for a specific patient who has no other treatment options. It acts like a one-off permission slip from health authorities or manufacturers to treat an individual, rather than a full product launch. Investors watch these programs because they can reveal early real-world demand, provide limited revenue and safety data, and signal potential future market acceptance — like a pilot test before a full product rollout.

compassionate care regulatory

"Program under the legal framework for compassionate care in South Africa"

Compassionate care is patient-focused medical support that prioritizes comfort, dignity and emotional support alongside clinical treatment, often during serious illness or end-of-life situations. Investors care because it shapes demand for services, affects reputations, regulatory scrutiny and reimbursement policies, and can create market opportunities for products or programs—think of it like customer service tailored for people in crisis rather than a one-size-fits-all transaction.

clinicaltrials.gov regulatory

"The US multicenter Phase 1/2a study of MP0712 (ClinicalTrials.gov: NCT07278479)"

clinicaltrials.gov is a publicly accessible U.S. government database that lists details, timelines and status updates for medical studies testing drugs, devices or procedures. For investors it acts like a public calendar and scoreboard—showing when trials start, are delayed, or report results—so it helps gauge a company’s development progress, regulatory risk and potential value impact before official earnings or approvals are announced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. ASCO takes place May 29-June 2 in Chicago, and SNMMI May 30-June 2 in Los Angeles.

MP0712 is a ²¹²Pb-based Radio-DARPin Therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. DLL3 is a highly relevant target for radiopharmaceutical therapy due to its abundant expression in tumors of patients with SCLC (present in >85% of tumors) and other aggressive neuroendocrine tumors, while expression in healthy tissues is low. MP0712 is being co-developed with Molecular Partners’ strategic partner Orano Med, a pioneer in targeted alpha therapy.

The US multicenter Phase 1/2a study of MP0712 (ClinicalTrials.gov: NCT07278479) is actively recruiting patients with dosing ongoing in the first cohort. The Phase 1/2a study objectives are to assess safety and determine a recommended Phase 2 dose for MP0712. Molecular Partners expects to share initial clinical data from this study in 2026.

Molecular Partners and the team of Dr. Mike Sathekge at the Nuclear Medicine Research Institute (NuMeRI) in South Africa presented first patient imaging and dosimetry data on MP0712 at the 8th Theranostics World Congress (TWC) in January 2026.

The data, generated with MP0712 carrying the diagnostic isotope ²⁰³Pb as part of a Named Patient Access Program under the legal framework for compassionate care in South Africa, showed specific uptake in tumor lesions and are supportive of the clinical development plans of MP0712 carrying the therapeutic isotope ²¹²Pb.

Details of the presentations:

ASCO 2026

[²¹²Pb] Pb-MP0712 in patients with small cell lung cancer and other Delta-like ligand 3-expressing solid tumors: A phase 1/2a study to assess safety, tolerability, and efficacy  

Abstract/Publication Number: TPS3176  
Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 
Poster Board: 302b
Location: Hall A – Posters and Exhibits
Date and Time: 30 May 2026, 1:30–4:30 pm local time

SNMMI 2026

A phase 1/2a study to assess safety, tolerability, and efficacy of [²¹²Pb] Pb-MP0712 in patients with small cell lung cancer (SCLC) and other Delta-like ligand 3 (DLL3)-expressing solid tumors

Abstract/Publication Number: 261055
Poster Session: POP08: Oncology: Discovery & Translational (Preclinical & Phase 0/1 human studies)
Poster Screen: 51
Location: Science Pavilion–South Hall GHJK
Date and Time: 2 June 2026, 11:30am-12:15pm local time (Meet-the-Author Session [MTA] 11)

The posters will be made available on Molecular Partners' website after the presentations.

About Radio-DARPins

Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors with the potential to unlock a broad range of cancer targets and indications. Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform for precise delivery of potent radioactive payloads to tumor lesions. Molecular Partners’ Radio-DARPins address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering approaches, while preserving the advantages of the small protein format.

About DARPin Therapeutics
DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic potential for high affinity and specificity, as well as small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. Powered by twenty years of DARPin leadership, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:
Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com 
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com 
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of the strategic review; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

What is MP0712, the DLL3-targeting Radio-DARPin being developed by Molecular Partners (MOLN)?

MP0712 is a 212Pb-based Radio-DARPin Therapy targeting DLL3 for small cell lung cancer and other neuroendocrine tumors. According to Molecular Partners, DLL3 is highly expressed in over 85% of SCLC tumors, with low expression in healthy tissue, supporting targeted radiopharmaceutical use.

What clinical trial is evaluating MP0712 for small cell lung cancer in 2026 for MOLN?

MP0712 is being evaluated in a US multicenter Phase 1/2a study (NCT07278479) actively recruiting patients. According to Molecular Partners, dosing is ongoing in the first cohort and the trial’s main goals are to assess safety and define a recommended Phase 2 dose.

When and where will Molecular Partners present MP0712 data at ASCO 2026?

Molecular Partners will present a trial-in-progress poster on MP0712 at ASCO 2026 on May 30, 2026, from 1:30–4:30 pm. According to Molecular Partners, the poster will appear in Hall A, Board 302b, in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session.

What are the details of Molecular Partners’ MP0712 presentation at SNMMI 2026?

At SNMMI 2026, MP0712 will be featured in poster POP08 on June 2, 2026, from 11:30 am–12:15 pm. According to Molecular Partners, the poster will be on Screen 51 in the Science Pavilion–South Hall GHJK with a Meet-the-Author session (MTA 11).

What early imaging and dosimetry data support MP0712 development for MOLN investors?

Early data from South Africa using MP0712 with diagnostic isotope 203Pb showed specific uptake in tumor lesions. According to Molecular Partners, these Named Patient Access Program results support clinical development of MP0712 carrying therapeutic isotope 212Pb in small cell lung cancer and other DLL3-expressing tumors.

When does Molecular Partners expect initial clinical data from the MP0712 Phase 1/2a trial?

Initial clinical data from the ongoing Phase 1/2a MP0712 study are expected in 2026. According to Molecular Partners, the current trial focuses on safety evaluation and identifying a recommended Phase 2 dose for patients with small cell lung cancer and DLL3-expressing solid tumors.

Where can investors find the MP0712 ASCO and SNMMI 2026 posters from Molecular Partners (MOLN)?

The MP0712 posters from ASCO and SNMMI 2026 will be made available on Molecular Partners’ website after the presentations. According to Molecular Partners, this online access will allow investors and clinicians to review the detailed trial-in-progress information.